UK's Labour Party Says It Supports Pharma Industry

6 April 1997

UK shadow Health Minister Tessa Jowell (Member of Parliament forDulwich) pledged that a future Labour government would protect and nurture the pharmaceutical industry, when she addressed key industry figures at an RDL Directors Forum luncheon to outline New Labour's blueprint to rebuild and strengthen the health service.

The meeting was held in February, but the backers of the RDL forum, presumably with the UK General Election now set for May 1 in mind, have just released a report of Ms Jowell's comments. The Association of the British Pharmaceutical Industry was not represented, as the lunch clashed with a meeting of its own, an ABPI spokesman told the Marketletter.

Ms Jowell is said to have promised debate on issues such as generic substitution and specialist prescriptions of expensive new drugs, and said that she clearly recognized the fears of pharmacists about the loss of resale price maintenance.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight